CN117462644A - Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof - Google Patents
Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof Download PDFInfo
- Publication number
- CN117462644A CN117462644A CN202311716040.1A CN202311716040A CN117462644A CN 117462644 A CN117462644 A CN 117462644A CN 202311716040 A CN202311716040 A CN 202311716040A CN 117462644 A CN117462644 A CN 117462644A
- Authority
- CN
- China
- Prior art keywords
- parts
- atrophic gastritis
- chronic atrophic
- chinese medicine
- traditional chinese
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 208000016644 chronic atrophic gastritis Diseases 0.000 title claims abstract description 77
- 239000003814 drug Substances 0.000 title claims abstract description 70
- 239000000203 mixture Substances 0.000 title claims abstract description 42
- 235000002722 Dioscorea batatas Nutrition 0.000 claims abstract description 11
- 235000006536 Dioscorea esculenta Nutrition 0.000 claims abstract description 11
- 240000001811 Dioscorea oppositifolia Species 0.000 claims abstract description 11
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 claims abstract description 11
- 241000132012 Atractylodes Species 0.000 claims abstract description 9
- 241000007126 Codonopsis pilosula Species 0.000 claims abstract description 9
- 244000173782 Ficus hirta Species 0.000 claims abstract description 9
- 244000303040 Glycyrrhiza glabra Species 0.000 claims abstract description 9
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 claims abstract description 9
- 244000197580 Poria cocos Species 0.000 claims abstract description 9
- 235000008599 Poria cocos Nutrition 0.000 claims abstract description 9
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 claims abstract description 8
- 235000011477 liquorice Nutrition 0.000 claims abstract description 8
- 239000002994 raw material Substances 0.000 claims abstract description 8
- 240000004638 Dendrobium nobile Species 0.000 claims abstract description 4
- 210000000952 spleen Anatomy 0.000 claims description 19
- 230000007812 deficiency Effects 0.000 claims description 13
- 210000004369 blood Anatomy 0.000 claims description 12
- 239000008280 blood Substances 0.000 claims description 12
- 206010054949 Metaplasia Diseases 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 238000002360 preparation method Methods 0.000 claims description 6
- 241000915604 Scutellaria barbata Species 0.000 claims description 5
- 239000000463 material Substances 0.000 claims description 5
- 241001523681 Dendrobium Species 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 238000002156 mixing Methods 0.000 claims description 4
- 206010067994 Mucosal atrophy Diseases 0.000 claims description 3
- 238000000034 method Methods 0.000 claims description 3
- 206010058314 Dysplasia Diseases 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000000843 powder Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 26
- 231100000331 toxic Toxicity 0.000 abstract description 2
- 230000002588 toxic effect Effects 0.000 abstract description 2
- 241000700159 Rattus Species 0.000 description 34
- 241000208340 Araliaceae Species 0.000 description 22
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 22
- 235000003140 Panax quinquefolius Nutrition 0.000 description 22
- 235000008434 ginseng Nutrition 0.000 description 22
- 210000002784 stomach Anatomy 0.000 description 20
- 230000002496 gastric effect Effects 0.000 description 17
- 229940079593 drug Drugs 0.000 description 13
- 208000007882 Gastritis Diseases 0.000 description 9
- 210000000056 organ Anatomy 0.000 description 8
- 208000004300 Atrophic Gastritis Diseases 0.000 description 7
- 230000001684 chronic effect Effects 0.000 description 7
- 230000003628 erosive effect Effects 0.000 description 7
- 210000002966 serum Anatomy 0.000 description 7
- 208000024891 symptom Diseases 0.000 description 7
- VZUNGTLZRAYYDE-UHFFFAOYSA-N N-methyl-N'-nitro-N-nitrosoguanidine Chemical compound O=NN(C)C(=N)N[N+]([O-])=O VZUNGTLZRAYYDE-UHFFFAOYSA-N 0.000 description 6
- 101710198144 Endopolygalacturonase I Proteins 0.000 description 5
- 108090001005 Interleukin-6 Proteins 0.000 description 5
- 208000002193 Pain Diseases 0.000 description 5
- 101710191566 Probable endopolygalacturonase I Proteins 0.000 description 5
- 230000037396 body weight Effects 0.000 description 5
- 108010092028 endopolygalacturonase II Proteins 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 210000001156 gastric mucosa Anatomy 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- 230000009466 transformation Effects 0.000 description 5
- 208000036495 Gastritis atrophic Diseases 0.000 description 4
- 206010017865 Gastritis erosive Diseases 0.000 description 4
- 208000023652 chronic gastritis Diseases 0.000 description 4
- 238000002575 gastroscopy Methods 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 230000001575 pathological effect Effects 0.000 description 4
- 230000001737 promoting effect Effects 0.000 description 4
- 239000011782 vitamin Substances 0.000 description 4
- 229940088594 vitamin Drugs 0.000 description 4
- 229930003231 vitamin Natural products 0.000 description 4
- 235000013343 vitamin Nutrition 0.000 description 4
- 208000004998 Abdominal Pain Diseases 0.000 description 3
- 206010000060 Abdominal distension Diseases 0.000 description 3
- 206010000087 Abdominal pain upper Diseases 0.000 description 3
- 244000163122 Curcuma domestica Species 0.000 description 3
- 235000003392 Curcuma domestica Nutrition 0.000 description 3
- 208000005718 Stomach Neoplasms Diseases 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 230000004087 circulation Effects 0.000 description 3
- 235000003373 curcuma longa Nutrition 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 206010017758 gastric cancer Diseases 0.000 description 3
- 230000007170 pathology Effects 0.000 description 3
- 201000011549 stomach cancer Diseases 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000013976 turmeric Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 230000004580 weight loss Effects 0.000 description 3
- 241000721047 Danaus plexippus Species 0.000 description 2
- 206010061218 Inflammation Diseases 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 241000203475 Neopanax arboreus Species 0.000 description 2
- 208000004880 Polyuria Diseases 0.000 description 2
- 241001631271 Prunus fasciculata Species 0.000 description 2
- 241000329195 Sparganium erectum Species 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- 208000037976 chronic inflammation Diseases 0.000 description 2
- 230000006020 chronic inflammation Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 206010061428 decreased appetite Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 230000035619 diuresis Effects 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 230000008451 emotion Effects 0.000 description 2
- 230000003203 everyday effect Effects 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 235000003642 hunger Nutrition 0.000 description 2
- 230000004054 inflammatory process Effects 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000004877 mucosa Anatomy 0.000 description 2
- 230000001105 regulatory effect Effects 0.000 description 2
- 238000005728 strengthening Methods 0.000 description 2
- 235000019605 sweet taste sensations Nutrition 0.000 description 2
- 206010003694 Atrophy Diseases 0.000 description 1
- 208000017667 Chronic Disease Diseases 0.000 description 1
- 241000756943 Codonopsis Species 0.000 description 1
- 238000008157 ELISA kit Methods 0.000 description 1
- 208000018522 Gastrointestinal disease Diseases 0.000 description 1
- 235000017443 Hedysarum boreale Nutrition 0.000 description 1
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 1
- 206010019375 Helicobacter infections Diseases 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 206010062717 Increased upper airway secretion Diseases 0.000 description 1
- 206010033661 Pancytopenia Diseases 0.000 description 1
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 1
- 208000006994 Precancerous Conditions Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 208000027418 Wounds and injury Diseases 0.000 description 1
- 208000031971 Yin Deficiency Diseases 0.000 description 1
- 206010000059 abdominal discomfort Diseases 0.000 description 1
- 208000019790 abdominal distention Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 230000003044 adaptive effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000022531 anorexia Diseases 0.000 description 1
- 210000000702 aorta abdominal Anatomy 0.000 description 1
- 229940107666 astragalus root Drugs 0.000 description 1
- 230000037444 atrophy Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 208000024389 cytopenia Diseases 0.000 description 1
- 230000006735 deficit Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 235000005911 diet Nutrition 0.000 description 1
- 230000037213 diet Effects 0.000 description 1
- 208000010643 digestive system disease Diseases 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- FGXWKSZFVQUSTL-UHFFFAOYSA-N domperidone Chemical compound C12=CC=CC=C2NC(=O)N1CCCN(CC1)CCC1N1C2=CC=C(Cl)C=C2NC1=O FGXWKSZFVQUSTL-UHFFFAOYSA-N 0.000 description 1
- 229960001253 domperidone Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 230000030135 gastric motility Effects 0.000 description 1
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 206010020718 hyperplasia Diseases 0.000 description 1
- 208000014674 injury Diseases 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000015689 metaplastic ossification Effects 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 230000035764 nutrition Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 238000010827 pathological analysis Methods 0.000 description 1
- 230000003285 pharmacodynamic effect Effects 0.000 description 1
- 208000026435 phlegm Diseases 0.000 description 1
- 208000022131 polyp of large intestine Diseases 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000012552 review Methods 0.000 description 1
- 235000000891 standard diet Nutrition 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- 230000001502 supplementing effect Effects 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002560 therapeutic procedure Methods 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 229940126680 traditional chinese medicines Drugs 0.000 description 1
- 238000010792 warming Methods 0.000 description 1
- 208000016261 weight loss Diseases 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/34—Campanulaceae (Bellflower family)
- A61K36/344—Codonopsis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
- A61K36/076—Poria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/23—Apiaceae or Umbelliferae (Carrot family), e.g. dill, chervil, coriander or cumin
- A61K36/233—Bupleurum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/28—Asteraceae or Compositae (Aster or Sunflower family), e.g. chamomile, feverfew, yarrow or echinacea
- A61K36/284—Atractylodes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/484—Glycyrrhiza (licorice)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/53—Lamiaceae or Labiatae (Mint family), e.g. thyme, rosemary or lavender
- A61K36/539—Scutellaria (skullcap)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/60—Moraceae (Mulberry family), e.g. breadfruit or fig
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/888—Araceae (Arum family), e.g. caladium, calla lily or skunk cabbage
- A61K36/8888—Pinellia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/894—Dioscoreaceae (Yam family)
- A61K36/8945—Dioscorea, e.g. yam, Chinese yam or water yam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/898—Orchidaceae (Orchid family)
- A61K36/8984—Dendrobium
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/902—Sparganiaceae (Bur-reed family)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/88—Liliopsida (monocotyledons)
- A61K36/906—Zingiberaceae (Ginger family)
- A61K36/9066—Curcuma, e.g. common turmeric, East Indian arrowroot or mango ginger
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/33—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones
- A61K2236/331—Extraction of the material involving extraction with hydrophilic solvents, e.g. lower alcohols, esters or ketones using water, e.g. cold water, infusion, tea, steam distillation, decoction
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/30—Extraction of the material
- A61K2236/39—Complex extraction schemes, e.g. fractionation or repeated extraction steps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/51—Concentration or drying of the extract, e.g. Lyophilisation, freeze-drying or spray-drying
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2236/00—Isolation or extraction methods of medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicine
- A61K2236/50—Methods involving additional extraction steps
- A61K2236/53—Liquid-solid separation, e.g. centrifugation, sedimentation or crystallization
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Alternative & Traditional Medicine (AREA)
- Neurosurgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Plant Substances (AREA)
Abstract
The invention discloses a traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof, wherein the traditional Chinese medicine composition is prepared from the following raw materials in parts by weight: 8-15 parts of codonopsis pilosula, 8-15 parts of bighead atractylodes rhizome, 8-15 parts of poria cocos, 8-12 parts of rhizoma sparganii, 25-35 parts of Ficus simplicissima lour, 10-20 parts of herba scutellariae barbatae, 25-35 parts of Chinese yam, 8-15 parts of dendrobium nobile, 6-10 parts of rhizoma pinellinae praeparata, 8-15 parts of radix bupleuri, 8-15 parts of radix curcumae and 4-10 parts of liquorice. The traditional Chinese medicine composition has exact treatment effect on the chronic atrophic gastritis, and provides a new medicine choice for treating the chronic atrophic gastritis. The traditional Chinese medicine composition is a pure traditional Chinese medicine prescription, has good clinical curative effect and small toxic and side effects, and is suitable for clinical popularization and application.
Description
Technical Field
The invention relates to the technical field of traditional Chinese medicines, in particular to a traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof.
Background
Chronic atrophic gastritis is one of the most common chronic digestive system diseases clinically, and is commonly considered as a precancerous condition of gastric cancer. Clinical symptoms of chronic atrophic gastritis such as stomach abdominal pain, inappetence, weight loss and the like are pathological features of chronic inflammation of gastric mucosa and cytopenia or loss of gastric gland, often accompanied by intestinal metaplasia, and finally gastric cancer is caused. Reversing precancerous lesions and improving the chronic atrophic gastritis state should be an important means to avoid gastric cancer. The pathogenesis of chronic atrophic gastritis is currently unknown, but is generally considered to be caused by repeated damage to gastric mucosa by physicochemical factors, helicobacter pylori infection and other factors.
At present, western medicine has no specific therapy for chronic atrophic gastritis, and has the advantages of eradicating helicobacter pylori, protecting gastric mucosa, promoting gastric motility (such as domperidone), supplementing mucosal nutrition (such as vitamin), and the like, along with poor curative effect, high recurrence rate and difficult cure. Therefore, development of a new traditional Chinese medicine composition for treating chronic atrophic gastritis is needed. Traditional Chinese medicine has a long history and unique advantages in treating gastrointestinal diseases.
Disclosure of Invention
In view of the above, the present invention aims to provide a traditional Chinese medicine composition for treating chronic atrophic gastritis, which has a good therapeutic effect on chronic atrophic gastritis.
The invention aims at realizing the following technical scheme:
a traditional Chinese medicine composition for treating chronic atrophic gastritis is prepared from the following raw materials in parts by weight:
8-15 parts of codonopsis pilosula, 8-15 parts of bighead atractylodes rhizome, 8-15 parts of poria cocos, 8-12 parts of rhizoma sparganii, 25-35 parts of Ficus simplicissima lour, 10-20 parts of herba scutellariae barbatae, 25-35 parts of Chinese yam, 8-15 parts of dendrobium nobile, 6-10 parts of rhizoma pinellinae praeparata, 8-15 parts of radix bupleuri, 8-15 parts of radix curcumae and 4-10 parts of liquorice.
As a further preferable scheme, the traditional Chinese medicine composition for treating chronic atrophic gastritis is prepared from the following raw materials in parts by weight:
10 parts of codonopsis pilosula, 10 parts of bighead atractylodes rhizome, 10 parts of poria cocos, 10 parts of rhizoma sparganii, 30 parts of Ficus simplicissima lour, 15 parts of barbed skullcap herb, 30 parts of Chinese yam, 10 parts of dendrobium, 9 parts of rhizoma pinellinae praeparata, 10 parts of radix bupleuri, 10 parts of radix curcumae and 6 parts of liquorice.
The traditional Chinese medicine composition is prepared from clinical laboratory prescriptions, and the codonopsis pilosula, the bighead atractylodes rhizome and the poria cocos are sweet in taste, all enter spleen channels, belong to qi-tonifying medicines, and are matched with the qi-tonifying medicines, and have the main effects of tonifying qi and strengthening spleen, warming but not drying, tonifying but not being drastic, and being slow in graph, and accords with the characteristics of sweet taste of spleen and stomach and light and slow medication. Spleen is preferred to dry and dislike dampness, spleen deficiency is easy to generate dampness, bai Zhu and Fu Ling are good at drying dampness and promoting diuresis besides strengthening spleen qi, so they are more suitable for patients with spleen deficiency and frequent dampness pathogen. Chronic gastritis is manifested as anorexia, debilitation, hunger, and deficiency of stomach qi, and is treated by spleen-invigorating and qi-tonifying, but not by drastic tonifying, and middle-jiao qi is smoothed. The five-finger wild peach, the Chinese yam, the common burreed rhizome and the turmeric root-tuber are ministerial, the five-finger wild peach is also called as astragalus root, belongs to the medicinal materials in the south of the Ling, has the effect of promoting diuresis in tonifying qi, and assists the monarch drug to tonify without stagnation; chinese yam can tonify spleen and promote the production of body fluid, assist monarch drugs to tonify qi, and give consideration to chronic atrophic gastritis with chronic diseases with yin impairment and stomach yin deficiency; chronic atrophic gastritis has longer disease course, long-term stasis, dark tongue, gastric cavity stabbing pain, fixed pain parts, common burreed rhizome and turmeric root-tuber, which both promote blood circulation and relieve pain, and turmeric root-tuber, which both promote qi circulation and relieve depression, and regulate the emotion of a patient for a long time. Herba Scutellariae Barbatae, herba Dendrobii, rhizoma Pinelliae Preparata, and bupleuri radix. The herba scutellariae barbatae is pungent, bitter and cold, has the effects of clearing heat and detoxicating, activating blood and dissolving stasis, relieving swelling and pain, is an anti-adjuvant drug of the recipe, enables the recipe to warm and tonify without warm dryness, slightly eliminates the dispersing force in the tonic drug, eliminates evil without hurting the vital energy, can dispel evil by means of the detoxifying and detumescence force, is suitable for chronic gastritis accompanied with mucosal atrophy, intestinal metaplasia and abnormal hyperplasia, has sweet taste and stomach channel returning force, nourishes yin and benefits the stomach, assists the Chinese yam to nourish stomach fluid, has the spleen deficiency and transportation and transformation functions, and has the effect of eliminating food microscopic accumulation and stagnation to form phlegm dampness, and is used for treating the rhizoma pinellinae praeparata, radix bupleuri qi circulation, stagnation removing dampness. Bupleuri radix enters liver meridian, is a good herb for promoting qi circulation and soothing liver, and assists radix Curcumae to regulate emotion. Licorice root, radix Glycyrrhizae Praeparata is used as a guiding drug for its actions of tonifying qi and regulating the middle warmer and harmonizing the drugs. The whole formula takes the effects of replenishing qi to invigorate the spleen, activating blood and removing stasis as a method, takes the effects of regulating qi, resolving masses and nourishing yin into account, is suitable for patients with spleen deficiency and blood stasis in chronic atrophic gastritis, and has definite curative effect on chronic atrophic gastritis.
The invention also provides a preparation method of the traditional Chinese medicine composition for treating chronic atrophic gastritis, which comprises the following steps:
decocting the above materials with 6-10 times of water for 2 times each for 1-2 hr, mixing extractive solutions, concentrating, and filtering.
The invention also provides application of the traditional Chinese medicine composition in preparing medicines for treating chronic atrophic gastritis.
As a further preferable scheme, the chronic atrophic gastritis is spleen deficiency and blood stasis type chronic atrophic gastritis.
As a further preferable embodiment, the chronic atrophic gastritis is chronic atrophic gastritis accompanied by mucosal atrophy, intestinal metaplasia, and dysplasia.
As a further preferred scheme, the medicament comprises an effective content of the traditional Chinese medicine composition and a pharmaceutically acceptable carrier. The medicament of the invention can be prepared into a proper dosage form by a conventional method in the field. Preferably, the medicament is in the form of mixture, tablet, capsule, pill, powder or granule.
Compared with the prior art, the invention has the following excellent effects:
according to the invention, a MNNG method is adopted to establish a rat chronic atrophic gastritis model, and the result shows that the traditional Chinese medicine composition can obviously improve stomach injury of a rat with MNNG-induced chronic atrophic gastritis, and improve weight loss, gastric atrophy degree and stomach tissue morphology of the rat. And the level of PG II can be obviously reduced, PG I and GAS can be increased, the content of inflammatory factors IL6 can be reduced, and the chronic atrophic gastritis rat gastric hormone and inflammatory factors can be obviously improved. The results show that the traditional Chinese medicine composition has an exact treatment effect on the chronic atrophic gastritis, and provides a new medicine choice for treating the chronic atrophic gastritis.
The traditional Chinese medicine composition for treating the chronic atrophic gastritis is a pure traditional Chinese medicine prescription, has good clinical curative effect and small toxic and side effects, and is suitable for clinical popularization and application.
Drawings
FIG. 1 is the effect of the ginseng stomach-nourishing formula on the weight of a rat with chronic atrophic gastritis;
FIG. 2 is the effect of the ginseng stomach-nourishing prescription on the index of the gastric organs of rats with chronic atrophic gastritis;
FIG. 3 is an external view of the stomach of each group of rats;
FIG. 4 shows the effect of the ginseng stomach-nourishing formulation on the serum biochemical index of rats with chronic atrophic gastritis;
FIG. 5 shows the effect of the ginseng stomach-nourishing formulation on the serum inflammatory factor index of rats with chronic atrophic gastritis.
Wherein Ctrl: blank group; model: a model group; vitacoenzyme: a group of vitamins; SZYW-L: a ginseng stomach nourishing prescription low dose group; SZYW-M: ginseng stomach nourishing prescription high dose group.
Detailed Description
The present invention will be further illustrated by the following examples, which are not intended to limit the scope of the invention.
Example 1:
a traditional Chinese medicine composition for treating chronic atrophic gastritis is prepared from the following raw materials in parts by weight:
10 parts of codonopsis pilosula, 10 parts of bighead atractylodes rhizome, 10 parts of poria cocos, 10 parts of rhizoma sparganii, 30 parts of Ficus simplicissima lour, 15 parts of barbed skullcap herb, 30 parts of Chinese yam, 10 parts of dendrobium, 9 parts of rhizoma pinellinae praeparata, 10 parts of radix bupleuri, 10 parts of radix curcumae and 6 parts of liquorice.
The preparation method comprises the following steps: decocting the above materials with 8 times of water for 1.5 hr, collecting extractive solution, adding 6 times of water into the residue, boiling for 1 hr, mixing extractive solutions, concentrating at 60deg.C, and filtering.
Example 2:
a traditional Chinese medicine composition for treating chronic atrophic gastritis is prepared from the following raw materials in parts by weight:
12 parts of codonopsis pilosula, 12 parts of bighead atractylodes rhizome, 12 parts of poria cocos, 8 parts of rhizoma sparganii, 25 parts of Ficus simplicissima lour, 10 parts of Scutellaria barbata, 35 parts of Chinese yam, 8 parts of dendrobium nobile, 6 parts of rhizoma pinellinae praeparata, 8 parts of radix bupleuri, 15 parts of radix curcumae and 4 parts of liquorice.
The preparation method is the same as in example 1.
Example 3:
a traditional Chinese medicine composition for treating chronic atrophic gastritis is prepared from the following raw materials in parts by weight:
15 parts of codonopsis pilosula, 15 parts of bighead atractylodes rhizome, 15 parts of poria cocos, 12 parts of rhizoma sparganii, 35 parts of Ficus simplicissima lour, 20 parts of barbed skullcap herb, 25 parts of Chinese yam, 12 parts of dendrobium, 10 parts of rhizoma pinellinae praeparata, 15 parts of radix bupleuri, 8 parts of radix curcumae and 5 parts of liquorice.
The preparation method is the same as in example 1.
Test example 1: pharmacodynamic study for treating chronic atrophic gastritis
1. Experimental materials
1.1 medicaments
Ginseng stomach nourishing formula: (radix Codonopsis 10g, atractylodis rhizoma 10g, poria 10g, rhizoma Sparganii 10g, ficus simplicissima lour 30g, herba Scutellariae Barbatae 15g, rhizoma Dioscoreae 30g, herba Dendrobii 10g, rhizoma Pinelliae Preparata 9g, bupleuri radix 10g, radix Curcumae 10g, glycyrrhrizae radix 6 g) were purchased from Nanjing Tongren Tang pharmacy in Dongguan, guangdong. Violet (CAS: 83-88-5, lot #: C14376028) was purchased from Shanghai Meilin Biochemical technologies Co.
The preparation method comprises the following steps: decocting crude drug with 8 times of water for 1.5 hr, collecting extractive solution, adding 6 times of water into the residue, boiling for 1 hr, mixing extractive solutions, concentrating at 60deg.C, and filtering to obtain concentrated solution.
1.2 reagents
MNNG (CAS: 70-25-7, lot#: C15811079) was purchased from Shanghai Michelin Biochemical technologies Co.
1.3 animals
SD rats (purchased from Liaoning Changsheng Biotechnology Co., ltd.) were male and had a body weight of 150-170g. Rats were kept in the university of medical science laboratory animal center (Dongguan school area) at 24-25℃and 70-75% humidity for 12 hours with light/darkness and free diet.
2. Experimental method
After 7 days of adaptive feeding (24-25 ℃, 70-75% humidity, 12 hours light/dark) with standard diet and water, rats were randomly divided into 2 groups, including a blank group and a model group. The blank group was free to drink water and the model group was continuously orally administered 200 μg/ml MNNG solution with hunger disorder (one day fasted, one day fed) for 8 weeks. After 8 weeks, rats in the model group were randomly divided into 4 groups, namely, a model group, a positive drug vitamin group (0.6 g/kg), a low-dose group of the ginseng stomach-nourishing prescription (7.191 g/kg) and a high-dose group of the ginseng stomach-nourishing prescription (14.39 g/kg). The low dose group and the high dose group of the ginseng stomach-nourishing prescription are filled with 1ml/100g of the corresponding dose medicine every day, and the model group and the positive medicine group are respectively administered with equivalent normal saline and vitamin for 4 weeks. At the end of the dosing period, the animals were anesthetized and the abdominal aorta was bled, sacrificed and the rats were sacrificed. Calculating organ indexes: organ index = organ mass/rat body weight.
After blood collection, centrifugation was carried out at 3000rpm for 10min, and the supernatant serum was collected and stored in sub-packages at-80 ℃. The amounts of PG I, PG II, GAS, IL6, etc. in serum were detected according to ELISA kit instructions.
The results were analyzed using Graphpad prism7.0 statistical analysis software. Each group of dataThe inter-sample comparison is shown using an ANOVA one-way analysis of variance.
3. Results and discussion
3.1 Effect of the stomach-nourishing formulation of Ginseng on the weight of rats with chronic atrophic gastritis
As shown in table 1 and fig. 1, after the end of the 12-week model dosing period, the model group body weight increased at a slower rate than the blank group, and the 12-week model group had a significant difference (P < 0.001) from the blank group body weight, and the participating stomach-nourishing low-dose group and the high-dose group increased the chronic atrophic gastritis rats body weight (P < 0.01).
Table 1. Influence of the ginseng stomach-nourishing prescription on the weight of rats with chronic atrophic gastritis (n=8)
Note that: the blank group with # p less than 0.05, # p less than 0.01 and # # p less than 0.001vs has statistical significance. * The differences are statistically significant in the model groups of p < 0.05, p <0.01, p <0.001 vs.
3.2 Effect of the stomach-nourishing prescription on the index of the gastric organs of rats with chronic atrophic gastritis
As shown in table 2 and fig. 2, the index of the gastric organ of the rats in the model group is obviously increased (P < 0.001) compared with the blank group, and the low-dose group and the high-dose group of the participating stomach nourishing formula can obviously reduce the index of the gastric organ of the rats with chronic atrophic gastritis (P < 0.01) and relieve the degree of gastric atrophy.
Table 2. Effect of Ginseng stomach-nourishing prescription on the index of gastric organs of rats with chronic atrophic gastritis (n=8)
Note that: the blank group with # p less than 0.05, # p less than 0.01 and # # p less than 0.001vs has statistical significance. * The differences are statistically significant in the model groups of p < 0.05, p <0.01, p <0.001 vs.
3.3 Effect of the stomach-nourishing formulation of Ginseng on the gastric appearance of rats with chronic atrophic gastritis
As shown in fig. 3, gastric mucosa of rats in blank group has dark red color, deep gastric folds and rich mucosa layer; the model group rats had lighter gastric tissue color and lighter gastric folds than the blank group. Compared with the stomach tissue of rats in the low dose group and the high dose group of the ginseng stomach nourishing prescription, the model group has darker color and more gastric folds.
3.4 Effect of the stomach-nourishing formulation of Ginseng on the serum Biochemical index of rats with chronic atrophic gastritis
As shown in table 3 and fig. 4, the model groups had reduced PG I and GAS levels compared to the blank group, and increased PG II levels (P < 0.01). The low and high doses of the ginseng stomach-nourishing formula can effectively increase the PG I and GAS contents (P < 0.001) and reduce the PG II contents (P < 0.01).
Table 3. Effect of Ginseng stomach-nourishing prescription on serum Biochemical index of rats with chronic atrophic gastritis (n=6)
Note that: the blank group with # p less than 0.05, # p less than 0.01 and # # p less than 0.001vs has statistical significance. * The differences are statistically significant in the model groups of p < 0.05, p <0.01, p <0.001 vs.
As shown in table 4 and fig. 5, the model group had an increased IL-6 content compared to the blank group, and the low-dose group and the high-dose group of the ginseng stomach-nourishing formula significantly reduced IL-6 level and chronic atrophic rat inflammation level.
Table 4. Effect of Ginseng stomach-nourishing prescription on serum inflammatory factor levels in rats with chronic atrophic gastritis (n=6)
Note that: the blank group with # p less than 0.05, # p less than 0.01 and # # p less than 0.001vs has statistical significance. * The differences are statistically significant in the model groups of p < 0.05, p <0.01, p <0.001 vs.
4. Conclusion(s)
The traditional Chinese medicine composition (ginseng stomach nourishing prescription) can effectively improve the weight loss and the gastric atrophy degree of the chronic atrophic gastritis rats, improve the gastric fold reduction of the chronic atrophic gastritis rats, increase the PG I and GAS contents of the chronic atrophic gastritis rats, and reduce the PG II content and the IL-6 level, which indicates that the traditional Chinese medicine composition can improve the stomach hormone level and the inflammation level of the chronic atrophic gastritis rats. In summary, the ginseng stomach nourishing recipe can effectively reverse chronic atrophic gastritis induced by MNNG.
Clinical cases:
(1) The women who are in village, 40 years old and 2022 are subjected to primary diagnosis on 10 months and 21 days, patients are subjected to repeated abdominal distension, and gastroscopy is carried out on 2022 and 6 months, so that chronic atrophic gastritis is prompted, and the symptoms of gastric fullness and spleen deficiency and blood stasis are diagnosed by traditional Chinese medicine, and the gastroscopy is reviewed on 2023, 10 months and 12 days after 1 year of treatment by adopting the traditional Chinese medicine composition in the patent, decocting the medicines for taking 1 dose each day: chronic non-atrophic gastritis with erosion, pathological diagnosis: (antrum of stomach) mild chronic non-atrophic gastritis is accompanied by erosion of the focal area. Follow-up for 2 months, the patient stops taking the medicine for 2 months at present, and no symptom recurrence is seen.
(2) Mr. Wei, 47 years old, 2021, 6 months and 18 days. For repeated abdominal pain visit, gastroscope 11 months in 2020: chronic superficial gastritis is accompanied by erosion, and pathology suggests intestinal transformation (+). The Chinese medicine is used for diagnosing epigastric pain, spleen deficiency and blood stasis, the Chinese medicine composition in the patent is adopted for decoction and administration, 1 dose per day, and after 5 months of treatment, the gastroscope is reviewed in 2021, 11 months and 19 days: erosive gastritis is accompanied by slight intestinal transformation, and pathological is mucosal chronic gastritis and intestinal transformation (+). The traditional Chinese medicine composition in the patent is continuously adopted, the medicine is decocted for taking 1 dose per day, and after 11 months of treatment, the gastroscope is reviewed at 2022, 10 and 28 days: erosive gastritis. Following 1 year, no abdominal discomfort was observed.
(3) Is easy for first-born, 50 years old, 2022, 5 months and 20 days old. Patient complains of 20 years upper abdominal distension, 2022 8 months 20 days gastroscope display: chronic atrophic gastritis C1 with erosion, enteroscope: colorectal polyps are numerous, the traditional Chinese medicine is used for diagnosing gastric fullness and spleen deficiency and blood stasis, the traditional Chinese medicine composition in the patent is adopted for decoction and administration, 1 dose is taken every day, and gastroscopy is rechecked for 9 months, 2023, 5 months and 31 days: erosive gastritis, the pathology is not changed by atrophy of mucous membrane. At present, the symptoms are obviously relieved.
(4) For women, 54 years old, 8 months and 26 days of 2022, as the upper abdominal distention and pain are nearly 3 years old, the history of chronic atrophic gastritis with intestinal metaplasia is provided, and the symptoms of epigastralgia and spleen deficiency and blood stasis are diagnosed by traditional Chinese medicine, the traditional Chinese medicine composition in the patent is adopted, and the medicine is decocted for taking 1 dose per day, and the gastroscope is rechecked for 8 months, 2023, 4 months and 18 days: chronic non-atrophic gastritis. The following treatment is carried out for half a year, and no symptom recurrence is seen.
(5) The first diagnosis of the women at the age of 41 years, at 7.16 days 2021, with the hidden pain in the epigastrium, at 7.16 days 2021, with gastroscopy: erosive gastritis is accompanied by intestinal metaplasia and atypical changes, and pathological results suggest chronic inflammation of the antral mucosa is accompanied by erosion, intestinal metaplasia and atypical changes. The Chinese medicine is used for diagnosing epigastric pain, spleen deficiency and blood stasis, the Chinese medicine composition in the patent is adopted for decoction and administration, 1 dose per day is used for treating 1 year, 2022, 7 months and 1 day is used for review of gastroscope: chronic non-atrophic gastritis. No recurrence was seen following 1 year of follow-up.
(6) For women in forests, 60 years old, 2022, 6, 23 days of initial diagnosis, for gastric distention, 2021, 7, 30 days of gastroscope of my hospital: chronic gastritis is accompanied by severe intestinal metaplasia, 28 th day of the hospital gastroscope in 2022, 3 months: chronic atrophic gastritis C1 with erosion and intestinal metaplasia. Pathological results: chronic atrophic gastritis of antrum, accompanied by erosion and intestinal transformation (++). The Chinese medicine is used for diagnosing the gastric fullness and spleen deficiency and blood stasis, the Chinese medicine composition in the patent is adopted for decoction and administration, 1 dose per day, and the gastroscope is reviewed in 8 months, 2023, 4 months and 7 days of treatment: chronic atrophic gastritis and pathology suggests the metaplasia of the intestinal lamina for mild chronic atrophic gastritis. At present, the symptoms are obviously relieved.
Claims (8)
1. The traditional Chinese medicine composition for treating the chronic atrophic gastritis is characterized by being prepared from the following raw materials in parts by weight:
8-15 parts of codonopsis pilosula, 8-15 parts of bighead atractylodes rhizome, 8-15 parts of poria cocos, 8-12 parts of rhizoma sparganii, 25-35 parts of Ficus simplicissima lour, 10-20 parts of herba scutellariae barbatae, 25-35 parts of Chinese yam, 8-15 parts of dendrobium nobile, 6-10 parts of rhizoma pinellinae praeparata, 8-15 parts of radix bupleuri, 8-15 parts of radix curcumae and 4-10 parts of liquorice.
2. The traditional Chinese medicine composition for treating chronic atrophic gastritis according to claim 1, which is characterized by being prepared from the following raw materials in parts by weight:
10 parts of codonopsis pilosula, 10 parts of bighead atractylodes rhizome, 10 parts of poria cocos, 10 parts of rhizoma sparganii, 30 parts of Ficus simplicissima lour, 15 parts of barbed skullcap herb, 30 parts of Chinese yam, 10 parts of dendrobium, 9 parts of rhizoma pinellinae praeparata, 10 parts of radix bupleuri, 10 parts of radix curcumae and 6 parts of liquorice.
3. The method for preparing the traditional Chinese medicine composition for treating chronic atrophic gastritis as claimed in claim 1 or 2, which is characterized by comprising the following steps:
decocting the above materials with 6-10 times of water for 2 times each for 1-2 hr, mixing extractive solutions, concentrating, and filtering.
4. The use of the Chinese medicinal composition according to claim 1 or 2 in the preparation of a medicament for treating chronic atrophic gastritis.
5. The use according to claim 4, wherein the chronic atrophic gastritis is chronic atrophic gastritis with spleen deficiency and blood stasis.
6. The use according to claim 4, wherein the chronic atrophic gastritis is chronic atrophic gastritis accompanied by mucosal atrophy, intestinal metaplasia, dysplasia.
7. The use according to claim 4, wherein the medicament comprises an effective amount of the Chinese medicinal composition and a pharmaceutically acceptable carrier.
8. The use according to claim 7, wherein the medicament is in the form of a mixture, tablet, capsule, pill, powder or granule.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311716040.1A CN117462644A (en) | 2023-12-14 | 2023-12-14 | Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311716040.1A CN117462644A (en) | 2023-12-14 | 2023-12-14 | Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117462644A true CN117462644A (en) | 2024-01-30 |
Family
ID=89634946
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311716040.1A Pending CN117462644A (en) | 2023-12-14 | 2023-12-14 | Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117462644A (en) |
-
2023
- 2023-12-14 CN CN202311716040.1A patent/CN117462644A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2002078722A1 (en) | An antineoplastic drug | |
| CN103536742B (en) | A kind ofly treat pharmaceutical composition of chronic enterogastritis disease and preparation method thereof | |
| CN113181292A (en) | Traditional Chinese medicine composition for treating constipation | |
| CN105832991B (en) | Traditional Chinese medicine composition for treating gastritis | |
| CN115770279B (en) | Traditional Chinese medicine composition for treating chronic lower limb vein diseases, decoction and preparation thereof | |
| CN111840456A (en) | Chinese medicinal composition for treating respiratory system diseases | |
| CN105055841A (en) | Medicine for treating chronic pharyngitis and preparing method thereof | |
| CN101327293B (en) | Capsules for treating peptic ulcer and preparation method thereof | |
| CN1404854A (en) | Medicine for treating nosal inflammation | |
| CN117462644A (en) | Traditional Chinese medicine composition for treating chronic atrophic gastritis and application thereof | |
| CN111407808B (en) | Traditional Chinese medicine composition and preparation method and pharmaceutical application thereof | |
| CN101693084B (en) | Medical composition for treating epigastric pain yin deficiency syndrome and preparation method thereof | |
| CN111184825B (en) | Traditional Chinese medicine formula for treating chronic atrophic gastritis turbid toxin syndrome | |
| CN104225016B (en) | A kind of pharmaceutical composition treating due to weakness of spleen and stomach chronic atrophic gastritis | |
| CN108514627B (en) | Traditional Chinese medicine composition for treating chronic urticaria | |
| CN113713031A (en) | Traditional Chinese medicine composition for treating helicobacter pylori infection, preparation method and application | |
| CN112870309A (en) | Application of traditional Chinese medicine composition in preparation of medicine for treating or improving gastrointestinal diseases | |
| CN1201772C (en) | Chinese medicine for treating chronic atrophic gastritis | |
| CN116920057B (en) | Traditional Chinese medicine composition for treating acute and chronic gastritis and application thereof | |
| CN111494583A (en) | A pharmaceutical composition for treating chronic atrophic gastritis and preparation method thereof | |
| CN110433271A (en) | A kind of pharmaceutical composition and its preparation method and application for treating functional dyspepsia FD | |
| CN104491816A (en) | Application of traditional Chinese medicinal composition in preparation of medicine for treating chronic gastroenteritis | |
| JPH0733676A (en) | Composition for lowering blood suger value | |
| CN111759901B (en) | Traditional Chinese medicine composition for treating functional abdominal pain of children and preparation method thereof | |
| CN109620923B (en) | Traditional Chinese medicine composition for treating recurrent oral ulcer and application thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |